Annual Drug Patent Expirations for INOMAX
Inomax is a drug marketed by Mallinckrodt Hosp and is included in one NDA. It is available from one supplier. There are fifteen patents protecting this drug and one Paragraph IV challenge.
Drug patent litigation for INOMAX.
The generic ingredient in INOMAX is nitric oxide. One supplier is listed for this compound. Additional details are available on the nitric oxide profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
